NCT05425719: Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects |
|
|
| Completed | 3 | 249 | US, RoW | MB-102, Relmapirazin, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR) | MediBeacon | Chronic Kidney Disease | 02/23 | 02/23 | | |
NCT05943977: A Bioequivalence and Efficacy Study of MB-102 (Relmapirazin) in Chinese Participants |
|
|
| Completed | 3 | 121 | RoW | MB-102 DMID, Relmapirazin, MB-102 OMID, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., MediBeacon | Kidney Diseases, Kidney Injury, Kidney Failure | 11/23 | 11/23 | | |
BTH-DREAM-PRIDE, NCT04948749: Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial |
|
|
| Recruiting | N/A | 792 | RoW | Drug Eluting Stent implantation, Maurora ® Sirolimus Eluting Stent implantation, Aggressive medical treatment, Dual antiplatelet therapy for 6 months, Risk factor management, Risk factor and life style management, Standard medical treatment, Dual antiplatelet therapy for 3 months | Beijing Tiantan Hospital | ICAD - Intracranial Atherosclerotic Disease, ICAS - Intracranial Atherosclerosis, Drug-eluting Stent, Stroke, Drug Eluting Stents (DES), Medical Treatment | 12/26 | 12/26 | | |
